Determinants of remission in a case series of medullary thyroid carcinoma

Background/aim: We aimed to present the clinical results of patients with medullary carcinoma under follow-up in our center and to determine parameters affecting remission and lymph node metastases. Material and methods: A retrospective analysis was performed of the medical records of 27 patients with MTC who were followed up between 2004 and 2020. Results: The mean age at diagnosis was 47.7 ± 14 years. The mean follow-up was 7.29 ± 4.9 years. Metastatic neck lymphadenopathy was detected in eight (29.6%) patients; none had distant metastasis at the time of diagnosis. The median tumor diameter was 1.50 (range: 0.4–6) cm. The median postoperative calcitonin level was 3.3 (range, 0.5–871) ng/L. Relapse occurred in 2 (range, 1–14) years after the first surgery in three (11.1%) patients. In the last visit, 7 (25.9%) patients had a structural incomplete response, and three (11.1%) patients had a biochemical incomplete response. Seventeen (59.3%) patients were in remission, no patients died of MTC or any other cause. Elevated postoperative calcitonin level was a significant prognostic parameter for remission (p = 0.12) and lymph node metastasis (p < 0.001). Conclusion: Elevated postoperative calcitonin level and perithyroid soft tissue invasion were significant prognostic parameters for remission and lymph node metastasis. Postoperative calcitonin level and calcitonin doubling time should be considered for prognostic and survival risk assessments.Key words: Thyroid cancer, medullary carcinoma, calcitonin, life expectancy

PDF

___

1. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25 (6): 567-610. doi: 10.1089/thy.2014.0335
2. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88 (5): 1139-1148. doi: 10.1002/ (sici)1097-0142(20000301)88:5<1139: aid-cncr26>3.0.co;2-z
3. Kukulska A, Krajewska J, Kolosza Z, Paliczka-Cieslik E, Kropinska A et al. The role of postoperative adjuvant radiotherapy in the local control in medullary thyroid carcinoma. Endocrine Connections 2019; 9 (1): 1-8. doi: 10.1530/EC-19-0387
4. Hadoux J, Schlumberger M. Chemotherapy and tyrosinekinase inhibitors for medullary thyroid cancer. Best Practice & Research: Clinical Endocrinology & Metabolism 2017; 31 (3): 335-347. doi: 10.1016/j.beem.2017.04.009
5. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Longterm course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Annals of Surgery 1990; 212 (4): 395-400; discussion-1. doi:10.1097/00000658-199010000-00002
6. Gimm O, Dralle H. Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 1997; 122 (6): 1124-1130. doi: 10.1016/ s0039-6060(97)90217-8
7. Yang JH, Lindsey SC, Camacho CP, Valente FO, GermanoNeto F et al. Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer. Clinical Endocrinology (Oxford) 2015; 83 (6): 938-942. doi: 10.1111/ cen.12657
8. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Annals of Surgery 1999; 229 (6): 880- 887. doi: 10.1097/00000658-199906000-00016
9. Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001; 130 (6): 1044-1049. doi: 10.1067/msy.2001.118380a
10. Fialkowski EA, Moley JF. Current approaches to medullary thyroid carcinoma, sporadic and familial. Journal of Surgical Oncology 2006; 94 (8): 737-747. doi: 10.1002/js o.20690
11. Bae SY, Jung SP, Choe JH, Kim JS, Kim JH. Prediction of lateral neck lymph node metastasis according to preoperative calcitonin level and tumor size for medullary thyroid carcinoma. The Kaohsiung Journal of Medical Sciences 2019; 35 (12): 772-777. doi: 10.1002/kjm2.12122
12. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. Journal of Clinical Endocrinology & Metabolism 2010; 95 (6): 2655-2663. doi: 10.1210/jc.2009-2368
13. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clinical Endocrinology (Oxford) 2004; 61 (3): 299-310. doi: 10.1111/j.1365-2265.2004.02037.x
14. Ismailov SI, Piulatova NR. Postoperative calcitonin study in medullary thyroid carcinoma. Endocrine-Related Cancer 2004; 11 (2): 357-363. doi: 10.1677/erc.0.0110357
15. Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG et al. Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 2005; 115 (8): 1445-1450. doi: 10.1097/01.mlg.0000168114.90852.a6
16. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clinical Endocrinology (Oxford) 1998; 48 (3): 265-273. doi: 10.1046/j.1365-2265.1998.00392.x
17. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, Group GTES. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism 2005; 90 (11): 6077-6084. doi: 10.1210/jc.2005-0044
18. Meijer JA, le Cessie S, van den Hout WB, Kievit J, Schoones JW et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clinical Endocrinology (Oxford) 2010; 72 (4): 534-542. doi: 10.1111/j.1365-2265.2009.03666.x